European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
New technologies—the best is yet to come	186
Nuclear imaging and therapy in oncology in Poland in 2021–2022	185
Correction to: Preclinical evaluation of 64Cu/177Lu‑labelled anti‑CD30 monoclonal antibody for theranostics in CD30‑positive lymphoma	172
Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics	155
Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma	148
External validation of a predictive model for post-treatment persistent disease by 131I whole-body scintigraphy in patients with differentiated thyroid cancer	133
Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer	123
The world of functional and molecular imaging is not only based on radiopharmaceuticals: may EJNMMI become the house of all the images’ interpreters?	123
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	121
[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques	114
Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting	110
Granzyme B PET imaging inflammation and remodeling in myocardial infarction	108
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	103
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands	99
EANM Springer Prizes 2021 awarded at EANM 2021	92
Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models	91
The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG	86
Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [18F]FDG lights up the way	82
A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer	82
Looking ahead	79
D. Taïeb and K. Pacak (Eds). Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology	78
Impact of tissue-independent positron range correction on [68Ga]Ga-DOTATOC and [68Ga]Ga-PSMA PET image reconstructions: a patient data study	78
EANM Springer Prizes 2020 awarded at EANM 2021	75
Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article “Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11	75
PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL)	75

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner	74
Ultra-short time imaging of total-body PET/CT for cancer pain-induced untenable body position	72
Feasibility of acquisitions using total-body PET/CT with a half-dose [68Ga]Ga-FAPI-04 activity in oncology patients	72
Finding our way through the labyrinth of dementia biomarkers	72
Artificial intelligence guided enhancement of digital PET: scans as fast as CT?	71
GCP III is not the “off-target” for urea-based PSMA ligands	69
Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging	69
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	69
Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC	68
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study	67
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	64
Federico Caobelli (Ed): Imaging of Inflammation and Infection in Cardiovascular Diseases	63
Luca Giovanella. Integrated Diagnostics and Theranostics of Thyroid Diseases	62
The validation of low-dose CT scans from the [18F]-FDG PET-CT scan to assess skeletal muscle mass in comparison with diagnostic neck CT scans	62
Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model	61
State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)	60
Hossein Jadvar and Patrick M. Colletti (Eds): Nuclear Medicine: the Essentials	59
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?	59
Errors in imaging reading and reporting	59
Alberto Signore (Editor-in-Chief) Nuclear medicine and molecular imaging	57
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	57
The ICPO Foundation—on the way toward collaborative growth of theranostics	56
Minutes to hours after a nuclear event: available radiation poisoning antidotes and practical considerations on possible urgent approaches	56
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)	56
Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers	56
99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types	55
Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks	53
Long axial field of view PET scanners: a road map to implementation and new possibilities	53
A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study	53
Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma	52
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	51
Nuclear imaging in the new ESC Guidelines: the age of maturity	51
Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis	51
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging	51
EANM-Springer Award winners 2023	51
Reducing the risks of nuclear war—the role of health professionals	51
Multi-parametric [18F]PI-2620 tau PET/MRI for the phenotyping of different Alzheimer’s disease variants	50
Reflections on Terbium-149: advancing preclinical research in targeted alpha therapy	49
Whole-body PET imaging of simian immunodeficiency virus using gp120-targeting probes fails to reveal regions of specific uptake in rhesus macaques	49
The untapped potential of dosomics for theranostics: shaping the future of personalized medicine	49
Correction to: Noradrenergic cardiac denervation is associated with gait velocity in Parkinson disease: a dual ligand PET study	49
Comparison of clinical performance between late and standard total-body [68 Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer	48
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	48
Sex-based differences in nuclear medicine imaging and therapy	47
PET/CT imaging with radiolabeled FAPI: new opportunities for diagnosis and treatment of thyroid cancer	47
FAPI PET/CT: a new kid on the block for RCC	46
PD-L1 − targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy	46
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer	45
Exploring the origins of frequent tau-PET signal in vermal and adjacent regions	44
Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma	44

Myocardial blood flow reference values for 13N-ammonia PET myocardial perfusion imaging in patients without flow-limiting coronary artery disease	44
On the rational use of thyroid scintigraphy in thyrotoxic patients in the age of integrated diagnostics	42
The EANM guideline on radioiodine therapy of benign thyroid disease	42
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies	42
Anne G. Osborn, Luke L. Linscott, Karen L. Salzman: Osborn’s Brain: Imaging, Pathology and Anatomy, 3rd Edition	41
Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1	41
Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken'	41
How nuclear imaging changed parathyroid surgical strategies through time	40
Evaluating the efficacy of [177Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer	40
Takayasu’s arteritis imaged by a LAFOV PET/CT system: better resolution leads to greater diagnostic certainty	40
The false myth of “iodine allergy” also in nuclear medicine	40
Letter to the editor concerning “Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor”	40
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	40
Towards molecular imaging-guided intervention theatres in oncology	39
Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings	39
Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center	39
The utility of [¹⁸F] FDG PET/CT in staging hidradenocarcinoma	39
Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features	39
Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease	38
Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models	38
[68 Ga]Ga-DOTATATE PET/CT versus [68 Ga]Ga-Exendin-4 PET/CT in the evaluation of metastatic insulinoma	38
Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer	38
[99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience	37
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	37
A novel deep-learning–based approach for automatic reorientation of 3D cardiac SPECT images	37
EANM procedural recommendations for managing the paediatric patient in diagnostic nuclear medicine	37
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology	37
Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma	37
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results	36
Can we use PET to quantify mu opioid receptors across the monkey brain, spinal cord and peripheral organs at the same time? Totally!	36
Role of sex hormones in modulating myocardial perfusion and coronary flow reserve	35
Tau aggregation following subcortical hemorrhage	35
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	35
Cinematic rendering of [18F]FDG-PET/MR	35
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1	35
TSPO imaging in animal models of brain diseases	35
Why bother with alpha particles?	35
Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)	34
Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?	34
Neural correlates of beneficial effects of young plasma treatment in aged mice: PET-SPM analyses and neuro-behavioural/molecular biological studies	34
CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans	34
International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism	34
About the source and consequences of 18F-FDG brain PET hypometabolism in short and long COVID-19	34
Mosaic pattern of skin granuloma annulare on [18F]FDG PET/CT	33
68Ga-FAPI PET/CT detected non-FDG-avid bone metastases in breast cancer	33
High-resolution radioluminescence microscopy of FDG uptake in an engineered 3D tumor-stoma model	33
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	33
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	33
Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging	33
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	33
Cadherin-17 as a target for the immunoPET of adenocarcinoma	33
[18F]FDG PET for mapping the cerebral glucose metabolic characteristics of drug-sensitive and drug-resistant epilepsy in pediatric patients	33
“Metabolic fingerprints” of cachexia in lung cancer patients	33
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand the	33
FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis	33
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	32
Hybrid cardiovascular imaging. A clinical consensus statement of the european association of nuclear medicine (EANM) and the european association of cardiovascular imaging (EACVI) of the ESC	32
Imaging of neuroinflammation due to repetitive head injury in currently active kickboxers	32
Persistent dysfunctions of brain metabolic connectivity in long-covid with cognitive symptoms	32
The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma	32
Enhanced detection of damaged myocardium and risk stratification in hypertrophic cardiomyopathy using integrated [68Ga]Ga-FAPI-04 PET/CMR imaging	32
Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans	32
Pulmonary embolism as an incidental finding in [15O]H2O PET/CT myocardial perfusion imaging	32
Long-term trends in total administered radiation dose from brain [18F]FDG-PET in children with drug-resistant epilepsy	31
Seasonal variation in D2/3 dopamine receptor availability in the human brain	31
EC50 images, a novel endpoint from PET target occupancy studies, reveal spatial variation in apparent drug affinity	31
A case of cerebral amyloid angiopathy with ipsilateral tau and contralateral amyloid PET uptake related to cadaveric dura mater implanted in childhood	31
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions	31
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer	31
Sex differences in coronary atherosclerotic plaque activity using 18F-sodium fluoride positron emission tomography	31
Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas	31
Reducing instability of inter-subject covariance of FDG uptake networks using structure-weighted sparse estimation approach	30
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	30
Impact of the COVID-19 pandemic on nuclear medicine departments in Europe	30
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer	29
Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging	29
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial	29
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary	29
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	29
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	29

[18F] AlF‑NOTA‑FAPI‑04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG	29
Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients	29
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T	29
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	29
New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective	29
ImmunoPET imaging–based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model	29
Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study	29
Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas	28
Quantitative analysis of myocardial blood flow in surgically revascularized and not revascularized myocardial segments. A pilot PET study	28
[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network	28
How to combine CTA, 99mTc-WBC SPECT/CT, and [18F]FDG PET/CT in patients with suspected abdominal vascular endograft infections?	28
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	28
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET	28
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients	28
Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial	27
Degree of amyloid-β burden could be indicative of the primary etiology underlying dementia	27
Diagnostic efficiency of [68 Ga]Ga-DOTA-FAPI-04 in differentiating periprosthetic hip joint infection and aseptic failure	27
Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier	27
Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	27
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457	27
18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy	27
The value of bone SPECT/CT in evaluation of foot and ankle arthrodesis and adjacent joint secondary osteoarthritis	27
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective	27
Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients	27
[18F]mFBG long axial field of view PET-CT without general anaesthesia reveals concise extension of neuroblastoma in a 9-month-old boy	27
External validation of an 18F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancer	26
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study	26
Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial	26
Joint EANM/SNMMI guideline on radiomics in nuclear medicine	26
Controversies of [68Ga]Ga-FAPI-46 and 2-[18F]FDG findings in metastatic melanoma	26
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	26
Early, non-invasive detection of radiation-induced lung injury using PET/CT by targeting CXCR4	26
Trigeminal nerve perineural invasion by an adenoid cystic carcinoma of the maxillary sinus, detected by 68Ga-PSMA	26
Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function	26
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	26
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	26
Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: A multicentre cohort study	26
Short-axis PET image quality improvement based on a uEXPLORER total-body PET system through deep learning	26
Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients	26
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	26
Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT	26
The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis	25
Unmasking disseminated streptococcal infection: role of FDG PET/CT in diagnosis and assessing response to antibiotic treatment	25
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	25
IE-CycleGAN: improved cycle consistent adversarial network for unpaired PET image enhancement	25
A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images	25
68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement	25
Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer	25
The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study	25
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition	25
Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion	24
Unique [18F]FDG PET imaging pattern of drug-induced acute generalized exanthematous pustulosis within the SCAR-spectrum	24
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors	24
Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant	24
Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga]Ga-PSMA-11 PET/CT images	24
Self-supervised neural network for Patlak-based parametric imaging in dynamic [18F]FDG total-body PET	23
Comparison of [18F]FAPI-42 and [18F]FDG PET/CT in the evaluation of systemic vasculitis	23
Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer	23
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences	23
Spiral volumetric optoacoustic tomography of reduced oxygen saturation in the spinal cord of M83 mouse model of Parkinson’s disease	23
Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome	23
Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy	23
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	23
Three-way multiplexing in prostate cancer patients — combining a bimodal sentinel node tracer with multicolor fluorescence imaging	23
Validation and utility of HepG2 xenograft model for hepatocellular carcinoma	23
Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes	23
This union must happen: Radiomics and LAFOV PET/CT as the power couple of nuclear medicine	22
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound	22
Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumo	22
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study	22
Spatiotemporal dynamics of brain function during the natural course in a dental pulp injury model	22
Ultra-fast high resolution whole-body SPECT after treatment with 153Sm-EDTMP using 3D-ring CZT: applying new technology to an old tracer	22
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study	22
Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor	22
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI	22
Fluorophore-conjugated 4-1BB antibody enables early detection of T-cell responses in inflammatory arthritis via NIRF imaging	22
On the factors affecting the liver SUV in [18F]FDG PET/CT imaging	22
Highlights of the 36th EANM Annual Congress 2023, from hometown Vienna, Austria: “A SYMPHONY OF SCIENCE”	21
Correction to: Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography	21
Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging	21
Regional myocardial perfusion imaging in predicting vessel-related outcome: interplay between the perfusion results and angiographic findings	21
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”	21
Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study	21
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	21
Correction to: A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization	21
Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients	21
Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma	21
Total-body PET/CT or LAFOV PET/CT? Axial field-of-view clinical classification	21
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?	21
Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study	21
Correction to: Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	21
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome	21
Correction to: Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy	21
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence	21
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model	21